Related Experiment Videos
[Serum markers for melanoma]
1Klinische Kooperationseinheit Dermato-Onkologie, Deutsches Krebsforschungszentrum Heidelberg/Universitätshautklinik Mannheim. selma.ugurel@haut.ma.uni-heidelberg.de
Summary
Serum markers like S100-beta, melanoma inhibitory activity (MIA), and lactate dehydrogenase (LDH) aid in monitoring melanoma. Elevated levels indicate tumor growth and poorer survival, but they cannot predict outcomes for tumor-free patients post-surgery.
Area of Science:
- Oncology
- Biochemistry
- Clinical Diagnostics
Context:
- Serum tumor markers are vital for cancer patient diagnosis, prognosis, and therapy monitoring.
- Current melanoma serum markers have limited clinical utility.
- Widely used markers include S100-beta, MIA, and LDH, correlating with tumor burden.
Purpose:
- To evaluate the clinical utility of serum markers (S100-beta, MIA, LDH) in melanoma management.
- To assess the role of these markers in detecting relapse, monitoring disease, and predicting survival.
- To determine the limitations of current serum markers for melanoma screening and diagnosis.
Summary:
- Serum concentrations of S100-beta, MIA, and LDH correlate closely with melanoma tumor load.
- Regular monitoring of S100-beta and MIA aids in early detection of tumor relapse.
- Elevated levels of S100-beta, MIA, or LDH in metastatic melanoma patients are associated with poorer overall survival.
- These markers can monitor disease course and therapy response in patients with distant metastases.
Impact:
- Serum markers S100-beta, MIA, and LDH are valuable for monitoring melanoma progression and treatment response.
- Their elevated levels serve as indicators of tumor growth and reduced survival in metastatic cases.
- Limitations exist as these markers are tumor-load dependent, precluding survival prediction in tumor-free post-surgical patients.
- Serum markers are not suitable for primary melanoma diagnosis or population screening.